FDA Closes Fresenius Kabi Recall of 4,643 Tyenne Vials
The FDA has terminated its Class I enforcement action over glass particles in Tyenne (tocilizumab-aazg) Injection, meaning the agency considers the recall carried out.
Every recalls & safety alerts report published for Lake Zurich, Illinois, newest first.
The FDA has terminated its Class I enforcement action over glass particles in Tyenne (tocilizumab-aazg) Injection, meaning the agency considers the recall carried out.
An FDA enforcement report lists a Class II, nationwide recall of one lot of 1% lidocaine HCl injection initiated on July 16, 2026.
An FDA enforcement report dated July 29, 2026 lists the nationwide Class II recall of a single lot of the 0.5% ropivacaine hydrochloride injection as ongoing.
An FDA enforcement report dated July 29, 2026 lists a nationwide Class II recall by Fresenius Kabi USA, LLC of one lot of lidocaine HCl injection.
An FDA enforcement report classifies the nationwide Class II recall of a single lot of 2% lidocaine injection as ongoing.
An FDA enforcement report dated July 29, 2026 lists the nationwide Class II recall as ongoing.